Ventana Preparing HPV Test Submission, Will Co-Market With ChromaVision
This article was originally published in The Gray Sheet
Executive Summary
Ventana Medical Systems plans to seek premarket approval for its Inform human papilloma virus (HPV) test by year-end as a follow-up screen for women whose Pap results show atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intra-epithelial lesions (LSIL)
You may also be interested in...
Digene Still Expecting HPV DNA Pap Test Primary Screen Approval By 2003
Digene will re-analyze pivotal study data to demonstrate clinical utility of its HPV DNA Pap test as a primary screen for cervical cancer in response to an FDA request for additional information
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.